LEUKEMIZATION OF FOLLICULAR LYMPHOMA: DIAGNOSTIC FEATURES AND CLINICAL COURSE OF A RARE FORM OF THE DISEASE
(Abstract release date: 05/19/16)
EHA Library. Nesterova E. 06/09/16; 134630; PB1730
Ms. Ekaterina Nesterova
Contributions
Contributions
Abstract
Abstract: PB1730
Type: Publication Only
Background
Follicular lymphoma is а frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has poorly prognosis
Aims
to characterize a group of patients with FL with leukemization and evaluate the efficacy of therapy (R-CHOP /R-FMC/high dose therapy (HDT))
Methods
Among 250 patients diagnosed with FL in National Research Center for Hematology, 18 (7, 2%) had characteristic FL-LP (by cytological blood smears and flow cytometry analysis). 8/18 patients had extranodal foci: lung, stomach, spleen, lumbar muscles, upper jaw, vertebrae. 17/18 patients had bone marrow involvement. Morphologically in biopsies of tumors in the majority of patients had a indolent FL (10/18 pts were diagnosed with I-II cytological grade of FL, nodular tumor growth and nodular-diffuse tumor growth in 14/18 pts). As first line therapy we used standard therapy (R-CHOP or R-FMC) or HDT with autoSCT
Results
Median follow-up was 66 months (range 12–217). The 5-year overall survival (OS) and progression-free survival (PFS) were: 70% (standard error 10) and 35% (15), respectively (Fig. 1 and 2), Median OS was not reached, median RFS was 3 years
Conclusion
FL with leukemization characterized by a low overall and disease-free survival. The most effective treatment regimens of this group are: R-CHOP with autoSCT or R-FMC. These courses allow a greater degree to achieve complete eradication of the tumor clone in the bone marrow. Given the recurrent course of the FL, the most expedient to conduct autoSCT in first-line therapy
Session topic: E-poster
Keyword(s): Follicular lymphoma, Leukemia cells, Prognostic factor
Type: Publication Only
Background
Follicular lymphoma is а frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has poorly prognosis
Aims
to characterize a group of patients with FL with leukemization and evaluate the efficacy of therapy (R-CHOP /R-FMC/high dose therapy (HDT))
Methods
Among 250 patients diagnosed with FL in National Research Center for Hematology, 18 (7, 2%) had characteristic FL-LP (by cytological blood smears and flow cytometry analysis). 8/18 patients had extranodal foci: lung, stomach, spleen, lumbar muscles, upper jaw, vertebrae. 17/18 patients had bone marrow involvement. Morphologically in biopsies of tumors in the majority of patients had a indolent FL (10/18 pts were diagnosed with I-II cytological grade of FL, nodular tumor growth and nodular-diffuse tumor growth in 14/18 pts). As first line therapy we used standard therapy (R-CHOP or R-FMC) or HDT with autoSCT
Results
Median follow-up was 66 months (range 12–217). The 5-year overall survival (OS) and progression-free survival (PFS) were: 70% (standard error 10) and 35% (15), respectively (Fig. 1 and 2), Median OS was not reached, median RFS was 3 years
Conclusion
FL with leukemization characterized by a low overall and disease-free survival. The most effective treatment regimens of this group are: R-CHOP with autoSCT or R-FMC. These courses allow a greater degree to achieve complete eradication of the tumor clone in the bone marrow. Given the recurrent course of the FL, the most expedient to conduct autoSCT in first-line therapy
Session topic: E-poster
Keyword(s): Follicular lymphoma, Leukemia cells, Prognostic factor
Abstract: PB1730
Type: Publication Only
Background
Follicular lymphoma is а frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has poorly prognosis
Aims
to characterize a group of patients with FL with leukemization and evaluate the efficacy of therapy (R-CHOP /R-FMC/high dose therapy (HDT))
Methods
Among 250 patients diagnosed with FL in National Research Center for Hematology, 18 (7, 2%) had characteristic FL-LP (by cytological blood smears and flow cytometry analysis). 8/18 patients had extranodal foci: lung, stomach, spleen, lumbar muscles, upper jaw, vertebrae. 17/18 patients had bone marrow involvement. Morphologically in biopsies of tumors in the majority of patients had a indolent FL (10/18 pts were diagnosed with I-II cytological grade of FL, nodular tumor growth and nodular-diffuse tumor growth in 14/18 pts). As first line therapy we used standard therapy (R-CHOP or R-FMC) or HDT with autoSCT
Results
Median follow-up was 66 months (range 12–217). The 5-year overall survival (OS) and progression-free survival (PFS) were: 70% (standard error 10) and 35% (15), respectively (Fig. 1 and 2), Median OS was not reached, median RFS was 3 years
Conclusion
FL with leukemization characterized by a low overall and disease-free survival. The most effective treatment regimens of this group are: R-CHOP with autoSCT or R-FMC. These courses allow a greater degree to achieve complete eradication of the tumor clone in the bone marrow. Given the recurrent course of the FL, the most expedient to conduct autoSCT in first-line therapy
Session topic: E-poster
Keyword(s): Follicular lymphoma, Leukemia cells, Prognostic factor
Type: Publication Only
Background
Follicular lymphoma is а frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has poorly prognosis
Aims
to characterize a group of patients with FL with leukemization and evaluate the efficacy of therapy (R-CHOP /R-FMC/high dose therapy (HDT))
Methods
Among 250 patients diagnosed with FL in National Research Center for Hematology, 18 (7, 2%) had characteristic FL-LP (by cytological blood smears and flow cytometry analysis). 8/18 patients had extranodal foci: lung, stomach, spleen, lumbar muscles, upper jaw, vertebrae. 17/18 patients had bone marrow involvement. Morphologically in biopsies of tumors in the majority of patients had a indolent FL (10/18 pts were diagnosed with I-II cytological grade of FL, nodular tumor growth and nodular-diffuse tumor growth in 14/18 pts). As first line therapy we used standard therapy (R-CHOP or R-FMC) or HDT with autoSCT
Results
Median follow-up was 66 months (range 12–217). The 5-year overall survival (OS) and progression-free survival (PFS) were: 70% (standard error 10) and 35% (15), respectively (Fig. 1 and 2), Median OS was not reached, median RFS was 3 years
Conclusion
FL with leukemization characterized by a low overall and disease-free survival. The most effective treatment regimens of this group are: R-CHOP with autoSCT or R-FMC. These courses allow a greater degree to achieve complete eradication of the tumor clone in the bone marrow. Given the recurrent course of the FL, the most expedient to conduct autoSCT in first-line therapy
Session topic: E-poster
Keyword(s): Follicular lymphoma, Leukemia cells, Prognostic factor
{{ help_message }}
{{filter}}